冠状动脉粥样硬化性心脏病患者血清基质金属蛋白酶9检测中的质量控制  

Quality control of serum matrix metalloproteinase-9 detection in patients with coronary artery disease

作　　者：董磊[1] 刘飒[1] 王绿娅[1] 

机构地区：[1]首都医科大学附属北京安贞医院北京市心肺血管疾病研究所实验研究中心,100029

出　　处：《中国医药》2010年第12期1120-1121,共2页China Medicine

基　　金：北京市科学技术委员会应用基础研究与战略高技术主题重大项目（190906006000091）

摘　　要：目的 通过检测不同类型冠状动脉粥样硬化性心脏病（冠心病）患者血清基质金属蛋白酶9（MMP-9）和质控样本,探讨＂即刻性＂质控法在科研实验室酶联免疫吸附法（ELISA）中的应用价值.方法 采用ELISA检测冠心病患者血清MMP-9,用＂即刻性＂质控法进行室内质量控制.结果 ELISA检测MMP-9板内变异系数值≤15%,血清MMP-9质控测定结果SI上限值为1.15,SI下限值为0.625,经与SI值表中第3天的2倍标准差进行比较,均在允许范围之内;与健康对照组、心绞痛患者组相比较,心肌梗死组患者血清MMP-9水平明显升高（P＜0.05）.结论 ＂即刻性＂质控法对科研实验室是一种行之有效的室内质量控制方法.：Objective To evaluate the ＂Instant Method＂ in enzyme-linked immunosorbent assay （ELISA）by detecting matrix metalloproteinase-9 （MMP-9） and to discuss the quality control in the serum in patients with coronary artery disease （CAD）. Methods The level of MMP-9 in the serum of patients with CAD was measured by MMP-9 ELISA Kit, and ＂Instant Method＂ was used for internal quality control. Results MMP-9 levels were measured in MMP-9 ELISA Kit and the coefficient of variance （CV） was no higher than 15%. The value of SI between 0.625 and 1.15 was in the acceptable range. The level of MMP-9 significantly increased in the serum of the patients with myocardial infarction compared with the health control and angina pectoris. Conclusion ＂Instant Method＂ is an effective approach for internal quality control.

关 键 词：基质金属蛋白酶类 酶联免疫吸附试验 "即刻性"质控法 

分 类 号：R927.11[医药卫生—药学]